Investors expect Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) to report upbeat results from a Phase III clinical trial of its Parkinson's disease psychosis treatment at the end of the month. Shares of the biopharmaceutical climbed 35 cents to close at $2.26.